Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0281ATC

SHP-77 Human Lung Specialized Cells

Tumor Cell Lines > Lung Cancer Cell Lines

Product Type: Human Lung Cancer Cell Lines

Species: Human

Cell Type: Other / Specialized Cells

Source Organ: Lung

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: SHP-77

  • Description
    SHP-77 is a human small cell lung carcinoma (SCLC) cell line established in 1977 from a non-encapsulated primary tumor in the apical upper lobe of the left lung of a 54-year-old Caucasian male patient. This cell line exhibits epithelial-like morphology with mixed growth properties, showing both loosely adherent clusters and suspension aggregates. Cytogenetic analysis reveals mutations in key oncogenic drivers including KRAS and TP53 (1). SHP-77 expresses various neuroendocrine differentiation markers such as L-dopa decarboxylase, dense core secretory granules, neural cell adhesion molecule (NCAM), and surface antigens CD56/CD57 (HNK-1/Leu-7). The cell line demonstrates tumorigenic potential in immunodeficient mice, making it valuable for studying SCLC progression and immunotherapy response.
  • Product Name
    SHP-77
  • Product Type
    Human Lung Cancer Cell Lines
  • Species
    Human
  • Source Organ
    Lung
  • Product Type
    Human Lung Cancer Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    The SHP-77 cell line is a versatile research model widely used in immune-oncology and cytotoxicity studies related to small cell lung carcinoma (SCLC). It serves as an in vitro target in 51Cr and 111In release cytotoxicity assays, facilitating the study of cytotoxic immune responses. In vivo, SHP-77 is used in xenograft models to evaluate immune reactivity in nude mice, particularly using cells and serum from SCLC patients. Furthermore, they play a crucial role in assessing the immune status and therapeutic response in individuals with small cell lung carcinoma (SCLC) who have undergone radiation or chemotherapy treatments, offering valuable insights into treatment efficacy and resistance mechanisms.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    RPMI 1640 + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you